Quarterly report pursuant to Section 13 or 15(d)

Schedule Of Reconciliation of Segment Performance (Details)

v3.10.0.1
Schedule Of Reconciliation of Segment Performance (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 31, 2018
Aug. 31, 2017
Aug. 31, 2018
Aug. 31, 2017
Segment Performance $ (2,699) $ (3,029) $ (6,874) $ (7,713)
Stock-based compensation (955) (383) (2,782) (1,469)
Financial income (expenses), net (1,070) 45 (3,164) (2,534)
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value 4,509   4,509 0
Transaction expenses related to GPP agreement (1,500)   (1,500)  
Share in losses of associated companies (202) (152) (732) (348)
Loss before income tax $ (1,917) $ (3,519) $ (10,543) $ (12,064)